ClinicalTrials.gg
CompletedNCT05799495Updated Oct 9, 2024Results posted

A Study to Understand the Effect and Safety of the Study Medicine PF-07817883 in Adults Who Have Symptoms of COVID-19 But Are Not Hospitalized

A Phase 2 interventional study of PF-07817883 and Placebo in SARS-CoV-2 Infection, sponsored by Pfizer. Completed at 53 sites in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2024-10-09.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 69 studies in COVID-19 by Pfizer — 4 open to participants now, 10 under way, 3 of them phase 3. COVID-19 · Pfizer.

Enrollment
11th of 41
240 · median 20
Started
2023
with 11 others
Phase 2
7 of 69
none open now
Registered
38th of 69
by date

Among the 69 studies in COVID-19 by Pfizer, this one is the 11th largest by enrollment of the 41 interventional ones that give a count, is one of 12 that started in 2023, is one of 7 in phase 2, and was the 38th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

4 of the 69 studies in COVID-19 by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in COVID-19 by Pfizer, or all of them as a file.
02

Study summary

The purpose of the study is to understand the effects and safety of PF-07817883 treatment. The study wants to know how PF-07817883 treatment lowers the level of the virus that causes COVID 19. To understand that samples are collected from adult participants who have the symptoms of COVID 19 but are not hospitalized.

The study is seeking for participants who:

  • are 18 years of age or older at the time of entering the study.
  • have a positive rapid antigen test within 48 hours before entering the study. Rapid antigen test is a test done to confirm the presence of a specific virus in the body.
  • have onset of signs or symptoms of COVID-19 within 5 days before entering the study.
  • have at least 1 of the specified signs or symptoms of COVID-19 present on the day of entering the study.

Around 228 participants with a confirmed case of COVID 19 are planned to be taken into the study. Participants will be randomly grouped to receive PF-07817883. Three groups will receive 100, 300, 600mg of PF-07817883 and one of the groups will receive placebo (a pill that doesn't have any medicines) orally every 12 hours for 5 days.

The study is going to last up to 5 weeks. This includes the initial period of selecting participants, participants receiving the medicine or the placebo and then a 4-week follow-up period after giving the participants the last medicine.

The study team will monitor how each participant is doing with the study treatment during the study.

03

Conditions studied

  • SARS-CoV-2 Infection

Browse trials for

Keywords

  • COVID-19
  • SARS COVID-19
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants ≥18 to \<65 years of age at the time of the Screening Visit.

    • may be enrolled.
    • All fertile participants must agree to use a highly effective method of .
  2. Confirmed SARS-CoV-2 infection as determined by RAT in NP specimen collected within 48 hours prior to randomization. Investigator sites will use test kits that are authorized for use in this study and the test result must be available to confirm eligibility.
  3. Initial onset of signs/symptoms attributable to COVID-19 within 5 days prior to the day of randomization and at least 1 of the specified signs/symptoms attributable to COVID-19 present on the day of randomization.

Exclusion criteria

Exclusion Criteria:

  1. Current need for hospitalization or anticipated need for hospitalization within 24h after randomization in the clinical opinion of the site investigator.
  2. Known medical history of active liver disease (other than nonalcoholic hepatic steatosis), including chronic or active or C infection, primary biliary cirrhosis, Class B or Class C, or acute liver failure.
  3. History of or other to any of the components of the study interventions, as determined by the investigator.
  4. Suspected or confirmed concurrent active systemic infection other than COVID-19 that may interfere with the evaluation of response to the study intervention.
  5. with ≥1 of the following:

    1. Solid organ (eg, liver, heart, lung or kidney) transplant recipient who is receiving immunosuppressive therapy.
    2. Receipt of CAR-T-cell therapy or HCT either within 2 years of transplantation or receiving immunosuppressive therapy.
    3. Moderate or severe primary immunodeficiency (eg, DiGeorge syndrome, Wiskott-Aldrich syndrome).
    4. Use of at least 1 of the following immune-weakening medications:

      iii. Has received equivalent to prednisone ≥20 mg daily for at least 14 consecutive days within 30 days prior to study entry.

      iv. Active treatment causing significant immunosuppression, including alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents, TNF blockers, or other highly immunosuppressive drugs such as biologics.

    5. Hematological (including leukemia, lymphoma and myeloma) or active immunosuppressive treatment for solid tumor.
    6. infection with \<200 mm3 from known medical history within the past 6 months of screening.
  6. known severe renal impairment ( of \<30 mL/min/1.73 m2 within 6 months of the screening visit, using the serum creatinine-based CKD-EPI formula12).
  7. Oxygen saturation of \<92% on room air obtained at rest within 24h prior to randomization.
  8. Has received or is expected to receive any other antiviral for the treatment of COVID 19, including remdesivir, PAXLOVID, molnupiravir, mAb treatment (within 30 days or 5 half-lives [whichever is longer] prior to screening) or received convalescent COVID-19 plasma within 12 months.
  9. Expected to receive any dose of a SARS-CoV-2 vaccine within 14 days of randomization or during the study.
  10. Current or previous administration with an product (drug or vaccine) within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer). Authorized or products with conditional approval are not considered investigational.
  11. Known prior participation in this trial
  12. Known history of any of the following abnormalities in clinical laboratory tests (within past 6 months of the screening visit):

    • T bili ≥2 × (except for Gilbert's syndrome)
    • or ALT ≥2.5 × ULN
    • Abs \<1000/mm3.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
240 participants (actual)

Study arms

  • Experimental
    Arm 1: low dose

    Drug: PF-07817883

  • Experimental
    Arm 2: medium dose

    Drug: PF-07817883

  • Experimental
    Arm 3: high dose

    Drug: PF-07817883

  • Placebo comparator
    Arm 4: Placebo

    Drug: Placebo

Interventions

  • Arm 1: low dose Arm 2: medium dose Arm 3: high dose

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Logarithm Base 10 (Log10) Transformed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Ribo Nucleic Acid (RNA) Level on Day 5

    Change from baseline in SARS-CoV-2 RNA level at Day 5 was analyzed using Mixed Effects Repeated Measures (MMRM) model with fixed effects including treatment, visit, visit by treatment interaction, and baseline viral load. Covariates included days from baseline since symptom onset (\<=3 versus \[vs.\] \>3 days), vaccination status (complete or partial vs. unvaccinated), baseline anti-N serology status and age at screening (years). Participants were excluded from the analysis if baseline viral load was less than 4\*log10 copies/milliliter, missing, or not detected.

    Time frame: Baseline (Day 1), Day 5

Secondary outcomes

  1. Change From Baseline in Log10 Transformed SARS-CoV-2 RNA Level on Days 3, 10 and 14

    Change from baseline in SARS-CoV-2 RNA level at Day 3, Day 10 and Day 14 were analyzed using MMRM model with fixed effects including treatment, visit, visit by treatment interaction, and baseline viral load. Covariates included days from baseline since symptom onset (\<=3 vs. \>3 days), vaccination status (complete or partial vs. unvaccinated), baseline anti-N serology status and age at screening (years). Participants were excluded from the analysis if baseline viral load was less than 4\*log10 copies/milliliter, missing, or not detected.

    Time frame: Baseline (Day 1), Day 3, Day 10 and Day 14

  2. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a study participant after administration of a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. An adverse event is considered a treatment-emergent adverse event (TEAE) if the event started on or after the study medication start date and time. An SAE was any untoward medical occurrence at any dose that: resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions) or resulted in congenital anomaly/birth defect or was considered an important medical event.

    Time frame: From start of study intervention up to 28 days after last dose of study intervention (up to 33 days)

  3. Number of Participants With Treatment Emergent Adverse Events (TEAEs) Leading to Discontinuations

    An AE was any untoward medical occurrence in a study participant after administration of a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. An adverse event is considered a treatment-emergent adverse event (TEAE) if the event started on or after the study medication start date and time. Participants with an AE record indicating the AE caused permanent discontinuation from the study were reported under discontinuations from study due to TEAEs. Permanent discontinuations from study intervention due to TEAEs included those participants who had an AE record that indicated that action taken with study treatment was drug withdrawn but AE did not cause the participant to be discontinued from study.

    Time frame: From start of study intervention up to 28 days after last dose of study intervention (up to 33 days)

  4. Number of Participants With Laboratory Test Abnormalities

    The following laboratory parameters were assessed according to pre-specified criteria for abnormalities: a) hematology; hemoglobin (gram per deciliter \[g/dL\]), (less than\[\<\]0.8\*lower limit of normal \[LLN\]), erythrocytes(10\^12/Liter \[L\])(\< 0.8\*LLN), lymphocytes(10\^9/L)(more than\[\>\]1.2\*upper limit of normal \[ULN\]), neutrophils(\> 1.2\*ULN and \< 0.8\*LLN), basophils(10\^9/L)(\> 1.2\*ULN) and eosinophils (10\^9/L)(\> 1.2\*ULN). b) clinical chemistry; bilirubin(mg/dL)(\> 1.5\*ULN), urea nitrogen(mg/dL)(\> 1.3\*ULN), creatinine(mg/dL)(\> 1.3\*ULN), potassium(milli equivalence per millilitre \[mEq/L\], (\< 0.9\*LLN and \> 1.1\*ULN), calcium (mg/dL)(\< 0.9\*LLN), bicarbonate(mEq/L)(\< 0.9\*LLN and \> 1.1\*ULN), glucose (mg/dL)(\> 1.5\*ULN), creatine kinase(units per litre \[U/L) (\> 2.0\* ULN), D-Dimer(nanogram per milliliter\[ng/mL\]), (\>1.5\*ULN) and c)urinalysis; bacteria (low power field \[LPF\]\>20). Number of participants with any laboratory abnormalities meeting pre-specified criteria are reported in this outcome measure.

    Time frame: From start of study intervention up to 28 days after last dose of study intervention (up to 33 days).

  5. Number of Participants Meeting Pre-defined Criteria of Vital Sign Abnormalities

    Vital signs included blood pressure and pulse rate and were assessed with the participant in the supine or seated position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Pre-defined criteria for vital sign abnormalities was as systolic blood pressure (millimeter of mercury \[mmHg\]): value \< 90, change \>= 30 increase and change \>= 30 decrease, diastolic blood pressure (mmHg): value \<50; change \>= 20 increase and change \>= 20 decrease, pulse rate (beats per minute \[bpm\]): value \< 40 and value \> 120.

    Time frame: From start of study intervention up to 28 days after last dose of study intervention (up to 33 days).

  6. Number of Participants Meeting Pre-defined Criteria For ECG Abnormalities

    Twelve lead ECGs were collected using an ECG machine that automatically calculated heart rate and measured PR interval, QT interval, and QT interval correct by Frederica formula (QTcF). ECG abnormalities included: PR interval (millisecond \[msec\]): value \>=280, change \>40 increase; QT interval aggregate (msec): value \> 500), QTcF interval (450 \< value =\< 480; 480 \< value =\< 500; value \> 500; 30 \< change \<= 60 increase and change \> 60 increase).

    Time frame: From baseline (Day 1) up to Day 10

07

Results

Posted Oct 9, 2024

Participant flow

Treatment (Up to 5 Days)
Participant flow — Treatment (Up to 5 Days)
MilestonePF-07817883 100mgPF-07817883 300mgPF-07817883 600mgPlacebo
Started40408080
Treated40397979
Completed39367775
Not completed1435
Withdrew: Adverse event0110
Withdrew: Non-compliance with study drug0001
Withdrew: Other0100
Withdrew: Withdrawal by subject1113
Withdrew: Randomized not treated0111
Follow Up (Up to 4 Weeks)
Participant flow — Follow Up (Up to 4 Weeks)
MilestonePF-07817883 100mgPF-07817883 300mgPF-07817883 600mgPlacebo
Started39377876
Completed39377776
Not completed0010
Withdrew: Withdrawal by subject0010

Outcome measures

PrimaryChange From Baseline in Logarithm Base 10 (Log10) Transformed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Ribo Nucleic Acid (RNA) Level on Day 5

Change from baseline in SARS-CoV-2 RNA level at Day 5 was analyzed using Mixed Effects Repeated Measures (MMRM) model with fixed effects including treatment, visit, visit by treatment interaction, and baseline viral load. Covariates included days from baseline since symptom onset (\<=3 versus \[vs.\] \>3 days), vaccination status (complete or partial vs. unvaccinated), baseline anti-N serology status and age at screening (years). Participants were excluded from the analysis if baseline viral load was less than 4\*log10 copies/milliliter, missing, or not detected.

Time frame:
Baseline (Day 1), Day 5
Reported as:
Least squares mean · Log10 copies/milliliter
Change From Baseline in Logarithm Base 10 (Log10) Transformed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Ribo Nucleic Acid (RNA) Level on Day 5
Log10 copies/milliliterPF-07817883 100mgPF-07817883 300mgPF-07817883 600mgPlacebo
Change From Baseline in Logarithm Base 10 (Log10) Transformed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Ribo Nucleic Acid (RNA) Level on Day 5-3.883 (-4.247 to -3.520)-4.015 (-4.452 to -3.578)-4.380 (-4.671 to -4.088)-3.213 (-3.517 to -2.908)
Statistical analysis
  • PF-07817883 100mg vs Placebo · Mixed Models Analysis · p = 0.0181 · Ls mean difference: -0.671 · 80% CI -1.080 to -0.262
  • PF-07817883 300mg vs Placebo · Mixed Models Analysis · p = 0.0127 · Ls mean difference: -0.802 · 80% CI -1.260 to -0.344
  • PF-07817883 600mg vs Placebo · Mixed Models Analysis · p = <.0001 · Ls mean difference: -1.167 · 80% CI -1.506 to -0.827
SecondaryChange From Baseline in Log10 Transformed SARS-CoV-2 RNA Level on Days 3, 10 and 14

Change from baseline in SARS-CoV-2 RNA level at Day 3, Day 10 and Day 14 were analyzed using MMRM model with fixed effects including treatment, visit, visit by treatment interaction, and baseline viral load. Covariates included days from baseline since symptom onset (\<=3 vs. \>3 days), vaccination status (complete or partial vs. unvaccinated), baseline anti-N serology status and age at screening (years). Participants were excluded from the analysis if baseline viral load was less than 4\*log10 copies/milliliter, missing, or not detected.

Time frame:
Baseline (Day 1), Day 3, Day 10 and Day 14
Reported as:
Least squares mean · Log10 copies/milliliter
Change From Baseline in Log10 Transformed SARS-CoV-2 RNA Level on Days 3, 10 and 14
Log10 copies/milliliterPF-07817883 100mgPF-07817883 300mgPF-07817883 600mgPlacebo
Day 3-2.006 (-2.371 to -1.641)-2.702 (-3.123 to -2.280)-2.546 (-2.818 to -2.274)-1.398 (-1.684 to -1.112)
Day 10-5.027 (-5.326 to -4.728)-5.085 (-5.423 to -4.748)-5.305 (-5.529 to -5.082)-5.091 (-5.332 to -4.851)
Day 14-5.682 (-5.913 to -5.451)-5.500 (-5.769 to -5.231)-5.826 (-6.009 to -5.643)-5.443 (-5.637 to -5.250)
Statistical analysis
  • PF-07817883 100mg vs Placebo · Mixed Models Analysis · p = 0.0378 · Ls mean difference: -0.608 · 80% CI -1.046 to -0.170
  • PF-07817883 300mg vs Placebo · Mixed Models Analysis · p = 0.0003 · Ls mean difference: -1.304 · 80% CI -1.782 to -0.826
  • PF-07817883 600mg vs Placebo · Mixed Models Analysis · p = <.0001 · Ls mean difference: -1.148 · 80% CI -1.509 to -0.788
  • PF-07817883 100mg vs Placebo · Mixed Models Analysis · p = 0.5931 · Ls mean difference: 0.064 · 80% CI -0.287 to 0.416
  • PF-07817883 300mg vs Placebo · Mixed Models Analysis · p = 0.5080 · Ls mean difference: 0.006 · 80% CI -0.369 to 0.381
  • PF-07817883 600mg vs Placebo · Mixed Models Analysis · p = 0.1692 · Ls mean difference: -0.214 · 80% CI -0.501 to 0.073
  • PF-07817883 100mg vs Placebo · Mixed Models Analysis · p = 0.1172 · Ls mean difference: -0.239 · 80% CI -0.497 to 0.019
  • PF-07817883 300mg vs Placebo · Mixed Models Analysis · p = 0.3979 · Ls mean difference: -0.056 · 80% CI -0.337 to 0.224
  • PF-07817883 600mg vs Placebo · Mixed Models Analysis · p = 0.0109 · Ls mean difference: -0.383 · 80% CI -0.595 to -0.170
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a study participant after administration of a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. An adverse event is considered a treatment-emergent adverse event (TEAE) if the event started on or after the study medication start date and time. An SAE was any untoward medical occurrence at any dose that: resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions) or resulted in congenital anomaly/birth defect or was considered an important medical event.

Time frame:
From start of study intervention up to 28 days after last dose of study intervention (up to 33 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsPF-07817883 100mgPF-07817883 300mgPF-07817883 600mgPlacebo
TEAEs25119
SAEs0100
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) Leading to Discontinuations

An AE was any untoward medical occurrence in a study participant after administration of a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. An adverse event is considered a treatment-emergent adverse event (TEAE) if the event started on or after the study medication start date and time. Participants with an AE record indicating the AE caused permanent discontinuation from the study were reported under discontinuations from study due to TEAEs. Permanent discontinuations from study intervention due to TEAEs included those participants who had an AE record that indicated that action taken with study treatment was drug withdrawn but AE did not cause the participant to be discontinued from study.

Time frame:
From start of study intervention up to 28 days after last dose of study intervention (up to 33 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Leading to Discontinuations
ParticipantsPF-07817883 100mgPF-07817883 300mgPF-07817883 600mgPlacebo
Discontinuations from study due to TEAEs0100
Permanent discontinuations from study intervention due to TEAEs0010
SecondaryNumber of Participants With Laboratory Test Abnormalities

The following laboratory parameters were assessed according to pre-specified criteria for abnormalities: a) hematology; hemoglobin (gram per deciliter \[g/dL\]), (less than\[\<\]0.8\*lower limit of normal \[LLN\]), erythrocytes(10\^12/Liter \[L\])(\< 0.8\*LLN), lymphocytes(10\^9/L)(more than\[\>\]1.2\*upper limit of normal \[ULN\]), neutrophils(\> 1.2\*ULN and \< 0.8\*LLN), basophils(10\^9/L)(\> 1.2\*ULN) and eosinophils (10\^9/L)(\> 1.2\*ULN). b) clinical chemistry; bilirubin(mg/dL)(\> 1.5\*ULN), urea nitrogen(mg/dL)(\> 1.3\*ULN), creatinine(mg/dL)(\> 1.3\*ULN), potassium(milli equivalence per millilitre \[mEq/L\], (\< 0.9\*LLN and \> 1.1\*ULN), calcium (mg/dL)(\< 0.9\*LLN), bicarbonate(mEq/L)(\< 0.9\*LLN and \> 1.1\*ULN), glucose (mg/dL)(\> 1.5\*ULN), creatine kinase(units per litre \[U/L) (\> 2.0\* ULN), D-Dimer(nanogram per milliliter\[ng/mL\]), (\>1.5\*ULN) and c)urinalysis; bacteria (low power field \[LPF\]\>20). Number of participants with any laboratory abnormalities meeting pre-specified criteria are reported in this outcome measure.

Time frame:
From start of study intervention up to 28 days after last dose of study intervention (up to 33 days).
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Test Abnormalities
ParticipantsPF-07817883 100mgPF-07817883 300mgPF-07817883 600mgPlacebo
Number of Participants With Laboratory Test Abnormalities441813
SecondaryNumber of Participants Meeting Pre-defined Criteria of Vital Sign Abnormalities

Vital signs included blood pressure and pulse rate and were assessed with the participant in the supine or seated position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Pre-defined criteria for vital sign abnormalities was as systolic blood pressure (millimeter of mercury \[mmHg\]): value \< 90, change \>= 30 increase and change \>= 30 decrease, diastolic blood pressure (mmHg): value \<50; change \>= 20 increase and change \>= 20 decrease, pulse rate (beats per minute \[bpm\]): value \< 40 and value \> 120.

Time frame:
From start of study intervention up to 28 days after last dose of study intervention (up to 33 days).
Reported as:
Count of participants · Participants
Number of Participants Meeting Pre-defined Criteria of Vital Sign Abnormalities
ParticipantsPF-07817883 100mgPF-07817883 300mgPF-07817883 600mgPlacebo
Systolic blood pressure; value < 90 (mmHg)0011
Systolic blood pressure; change >= 30 (mmHg) increase0010
Systolic blood pressure; change >= 30 (mmHg) decrease1203
Diastolic blood pressure; value <50 (mmHg)0000
Diastolic blood pressure; change >= 20 (mmHg) increase1112
Diastolic blood pressure; change >= 20 (mmHg) decrease0022
Pulse rate; value < 40 (bpm)0000
Pulse rate; value > 120 (bpm)0000
SecondaryNumber of Participants Meeting Pre-defined Criteria For ECG Abnormalities

Twelve lead ECGs were collected using an ECG machine that automatically calculated heart rate and measured PR interval, QT interval, and QT interval correct by Frederica formula (QTcF). ECG abnormalities included: PR interval (millisecond \[msec\]): value \>=280, change \>40 increase; QT interval aggregate (msec): value \> 500), QTcF interval (450 \< value =\< 480; 480 \< value =\< 500; value \> 500; 30 \< change \<= 60 increase and change \> 60 increase).

Time frame:
From baseline (Day 1) up to Day 10
Reported as:
Count of participants · Participants
Number of Participants Meeting Pre-defined Criteria For ECG Abnormalities
ParticipantsPF-07817883 100mgPF-07817883 300mgPF-07817883 600mgPlacebo
PR Interval, value >= 280 (msec)0000
PR Interval, change > 40 increase (msec)0210
QT Interval (msec) value >5000000
QTcF Interval, 450 < value =< 480 (msec)1126
QTCF Interval, 480 < value =< 500 (msec)0000
QTCF Interval, value > 500 (msec)0000
QTCF Interval, 30 < change <= 60 increase (msec)5669
QTCF Interval, change > 60 increase (msec)0000

Adverse events

Collected over From start of study intervention up to 28 days after last dose of study intervention (up to 33 days).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PF-07817883 100mg0/40 (0%)0/40 (0%)0/40 (0%)
PF-07817883 300mg0/39 (0%)1/39 (2.6%)1/39 (2.6%)
PF-07817883 600mg0/79 (0%)0/79 (0%)2/79 (2.5%)
Placebo0/79 (0%)0/79 (0%)4/79 (5.1%)
Most frequent serious events
Most frequent serious events
EventPF-07817883 100mgPF-07817883 300mgPF-07817883 600mgPlacebo
Supraventricular extrasystolesCardiac disorders0/401/390/790/79
Most frequent other events
Most frequent other events
EventPF-07817883 100mgPF-07817883 300mgPF-07817883 600mgPlacebo
Alanine aminotransferase increasedInvestigations0/401/392/794/79

Baseline characteristics

The full analysis set (FAS) included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention Participants were analyzed according to the intervention they were actually randomized.

Age, Continuous
Age, Continuous(Years)PF-07817883 100mgPF-07817883 300mgPF-07817883 600mgPlaceboTotal
Mean43.6 ± 12.3041.9 ± 11.3141.4 ± 11.6041.5 ± 12.9741.9 ± 12.10
Sex: Female, Male
Sex: Female, Male(Participants)PF-07817883 100mgPF-07817883 300mgPF-07817883 600mgPlaceboTotal
Female23295045147
Male1710293490
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PF-07817883 100mgPF-07817883 300mgPF-07817883 600mgPlaceboTotal
Hispanic or Latino35316364193
Not Hispanic or Latino58151543
Unknown or Not Reported00101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PF-07817883 100mgPF-07817883 300mgPF-07817883 600mgPlaceboTotal
American Indian or Alaska Native00000
Asian126211
Native Hawaiian or Other Pacific Islander00000
Black or African American0212620
White39356069203
More than one race00000
Unknown or Not Reported00123
08

Study locations

53 sites
  • Cullman Clinical Trials
    Cullman, Alabama 35055, United States
  • ClinMed
    Phoenix, Arizona 85004, United States
  • Epic Medical Research - Surprise
    Surprise, Arizona 85378, United States
  • Applied Research Center of Arkansas
    Little Rock, Arkansas 72212, United States
  • Franco Felizarta, Md
    Bakersfield, California 93301, United States
  • Hope Clinical Research, Inc.
    Canoga Park, California 91303, United States
  • Velocity Clinical Research, Chula Vista
    Chula Vista, California 91911, United States
  • Benchmark Research
    Colton, California 92324, United States
  • Ascada Health PC dba Ascada Research
    Fullerton, California 92835, United States
  • Long Beach Clinical Trials
    Long Beach, California 90806, United States
  • Marvel Clinical Research - Santa Ana
    Santa Ana, California 92704, United States
  • Herco Medical and Research Center Inc
    Coral Gables, Florida 33134, United States
  • Advance Clinical Research Group
    Cutler Bay, Florida 33157, United States
  • Proactive Clinical Research,LLC
    Fort Lauderdale, Florida 33308, United States
  • Unlimited Medical Research Group LLC
    Hialeah Gardens, Florida 33018, United States
  • Qway Research LLC
    Hialeah, Florida 33010, United States
  • Palm Springs Community Health Center
    Miami Lakes, Florida 33014, United States
  • Angels Clinical Research Institute
    Miami, Florida 33122, United States
  • South Florida Research Center
    Miami, Florida 33135, United States
  • USPA Advance Concept Medical Research Group
    Miami, Florida 33143, United States
  • Bio-Medical Research LLC
    Miami, Florida 33144, United States
  • Coral Research Clinic Corp
    Miami, Florida 33186, United States
  • DBC Research USA
    Pembroke Pines, Florida 33029, United States
  • GCP Research, Global Clinical professionals
    Saint Petersburg, Florida 33705, United States
  • Javara - Privia Medical Group Georgia - Albany
    Albany, Georgia 31707, United States
  • Centricity Research Columbus Georgia Multispecialty
    Columbus, Georgia 31904, United States
  • Centricity Research Columbus Acute Care
    Columbus, Georgia 31909, United States
  • Rophe Adult and Pediatric Medicine/SKYCRNG
    Union City, Georgia 30291, United States
  • Snake River Research
    Idaho Falls, Idaho 83404, United States
  • University of Massachusetts Chan Medical School
    Worcester, Massachusetts 01655, United States
  • Great Lakes Research Group, Inc.
    Bay City, Michigan 48706, United States
  • Mercury Street Medical Group, PLLC
    Butte, Montana 59701, United States
  • Henderson Clinical Trials
    Henderson, Nevada 89052, United States
  • Excel Clinical Research, LLC
    Las Vegas, Nevada 89109, United States
  • Monroe Biomedical Research
    Monroe, North Carolina 28112, United States
  • Accellacare - Wilmington
    Wilmington, North Carolina 28401, United States
  • Wellnow Urgent Care and Research
    Cincinnati, Ohio 45215, United States
  • Remington-Davis, Inc
    Columbus, Ohio 43215, United States
  • WellNow Urgent Care & Research
    Dayton, Ohio 45424, United States
  • Kur Research @ Bon Secours Mercy Health, Inc - Urgent Care Easley
    Easley, South Carolina 29640, United States
  • Javara - Privia Medical Group Gulf Coast - The Woodlands PGTW
    Conroe, Texas 77384, United States
  • Javara - Privia Medical Group Gulf Coast - Cypress
    Cypress, Texas 77433, United States
  • DFW Clinical Research
    Dallas, Texas 75234, United States
  • Proactive Clinical Research LLC
    Edinburg, Texas 78539, United States
  • Next Level Urgent Care
    Houston, Texas 77057, United States
  • Laguna Clinical Research
    Laredo, Texas 78041, United States
  • Epic Clinical Research
    Lewisville, Texas 75057, United States
  • BFHC Research, LLC
    San Antonio, Texas 78249, United States
  • Consano Clinical Research, LLC
    Shavano Park, Texas 78231, United States
  • Javara - Privia Medical Group Gulf Coast - The Woodlands PGTW
    Shenandoah, Texas 77384, United States
  • Javara - Privia Medical Group North Texas - Stephenville
    Stephenville, Texas 76401, United States
  • Javara - Privia Medical Group Gulf Coast - The Woodlands PGTW
    The Woodlands, Texas 77384, United States
  • Eastside Research Associates
    Redmond, Washington 98052, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Sep 2023, 3 months.

Results were first posted in Oct 2024, 1 year after primary completion.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 3 months is below that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2023
First posted
Apr 5, 2023
StartActual
May 23, 2023
Primary completionActual
Sep 13, 2023
CompletionActual
Oct 11, 2023
Results first posted
Oct 9, 2024
Last update
Oct 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05799495
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Apr 5, 2023
Start date
May 23, 2023
Primary completion
Sep 13, 2023
Completion
Oct 11, 2023
Results posted
Oct 9, 2024
Last update
Oct 9, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibuzatrelvir

Start the discussion